Group 1 - The stock price of Weier Pharmaceutical is reported at 30.47 yuan, down by 1.81 yuan or 5.61% from the previous trading day, with a trading volume of 43,437 hands and a turnover of 132 million yuan [1] - In the first half of 2025, the company achieved operating revenue of 674 million yuan, a year-on-year decrease of 2.1%, and a net profit attributable to shareholders of 72.77 million yuan, down 7.77% year-on-year [1] - Shareholder Tang Qunsong has pledged 3.15 million shares, accounting for 22.32% of his holdings, with a total of 9.6 million shares pledged, representing 68.03% of his holdings as of the announcement date [1] Group 2 - As of the end of the second quarter of 2025, institutional investors held a total of 18.58 million shares of Weier Pharmaceutical, accounting for 13.72% of the total share capital, a decrease of 0.66 percentage points from the previous quarter [1] - The net outflow of main funds from Weier Pharmaceutical today is 25.94 million yuan, accounting for 0.63% of the circulating market value, with a cumulative net outflow of 40.39 million yuan over the past five days, representing 0.98% of the circulating market value [1]

| 股东 | 是否 为控 | 本次质 押股数/ | 是否 为限 | 是否 补充 | 质押 | 质押 | 质权人 | 占其所 持股份 | 占公司 总股本 | 质押融 资资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股股 东 | 万股 | 售股 | 质押 | 起始日 | 到期日 | | 比例 | 比例 | 用途 | | 唐群松 | 否 | 315 | 否 | 否 | 2025-8-19 | 2027-8-18 | 中国银 河证券 股份有 限公司 | 22.32% | 2.33% | 自身资 金需求 | 一、本次股份质押情况 二、股东累计质押股份情况 截至公告披露日，上述股东唐群松累计质押股份如下： 证券代码：603351 证券简称：威尔药业 公告编号：2025-025 南京威尔药业集团股份有限公司 关于持股5%以上股东股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司（以 ...

Core Viewpoint - The announcement from Weir Pharmaceutical indicates that major shareholder Tang Qunsong has pledged 3.15 million shares, which represents 22.32% of his holdings and 2.33% of the company's total share capital [1] Summary by Relevant Sections - **Share Pledge Details** - The pledge started on August 19, 2025, and is set to expire on August 18, 2027 [1] - The pledgee is China Galaxy Securities Co., Ltd. [1] - **Current Pledge Status** - As of the announcement date, Tang Qunsong has cumulatively pledged 9.6 million shares, which accounts for 68.03% of his total holdings and 7.09% of the company's total share capital [1]

Policy Developments - The National Health Commission and five other departments released measures to enhance the experience of family doctor contract services, focusing on improving service quality and health management for residents [2] Drug and Device Approvals - Novo Nordisk's Wegovy (semaglutide 2.4mg) received FDA approval for treating metabolic-associated fatty liver disease (MASH) with moderate to severe liver fibrosis, which is expected to boost sales [3] - Yiling Pharmaceutical's new traditional Chinese medicine, "Children's Lianhua Qinggan Granules," has received acceptance for its new drug registration application [4] - Pumen Technology obtained a medical device registration certificate for its high-sensitivity cardiac troponin I testing kit, which aids in diagnosing myocardial infarction [5] Financial Reports - Ping An Good Doctor reported a 19.5% increase in revenue to approximately 2.502 billion yuan and a net profit increase of 136.8% to 134 million yuan for the first half of the year [6] - Weier Pharmaceutical's revenue decreased by 2.1% to 674 million yuan, with a net profit decline of 7.77% to 72.77 million yuan in the same period [7] Capital Market Activities - Jianzhijia plans to sell its Qinhuangdao logistics center assets for approximately 24 million yuan, which does not constitute a related party transaction [8] - Gilead Sciences announced a placement of 52.4 million shares at a discount of about 9.9%, with expected net proceeds of approximately 467.69 million HKD, primarily for clinical trials related to obesity [9] Industry News - The National Disease Control Bureau reported a decline in new cases of Chikungunya fever in Foshan, with daily cases dropping from over 600 to below 100, indicating effective control measures [10] - A breakthrough study from Harvard University demonstrated the ability to induce human pluripotent stem cells to initiate meiosis, offering new hope for addressing infertility [11] Public Sentiment Alerts - Baiotai announced that Xinyu Qiheng reduced its stake by 0.78%, selling 3.2169 million shares and raising approximately 105 million yuan [12]

Core Viewpoint - Weir Pharmaceuticals (603351.SH) reported its semi-annual results for 2025, highlighting the current institutional investor holdings and changes in share ownership [1] Institutional Holdings - As of August 19, 2025, three institutional investors disclosed holding a total of 18.5823 million shares of Weir Pharmaceuticals, representing 13.72% of the company's total share capital [1] - The institutional holding percentage decreased by 0.66 percentage points compared to the previous quarter [1] Public Fund Holdings - Three public funds were disclosed this period, including Huaxia CSI 500 Index Enhanced A, Dongxing Lianzhong One-Year Holding Period Mixed A, and Dongxing Pharmaceutical Biotechnology Quantitative Stock Selection Mixed A [1] Social Security Fund Holdings - One new social security fund disclosed holding Weir Pharmaceuticals, namely Guotai Fund Management Co., Ltd. - Social Security Fund 2103 Portfolio [1] - One previously undisclosed social security fund, the National Social Security Fund 112 Portfolio, was also noted [1]

Core Viewpoint - Weir Pharmaceuticals reported a decline in both revenue and net profit for the first half of 2025 compared to the same period in the previous year [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 674 million yuan, representing a year-on-year decrease of 2.1% [2] - The net profit attributable to shareholders was around 72.77 million yuan, which is a year-on-year decrease of 7.77% [2] - Basic earnings per share were 0.54 yuan, reflecting a year-on-year decrease of 6.9% [2]

Core Viewpoint - The announcement provides an overview of Nanjing Well Pharmaceutical Group Co., Ltd.'s 2025 semi-annual report, emphasizing the company's commitment to transparency and accuracy in its financial disclosures [4][6]. Company Overview - Nanjing Well Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical excipients and synthetic lubricating base oil products [4]. Financial Data - The semi-annual report includes key operational data, although specific figures for production, sales, and revenue are not detailed in the provided text [4]. - The report indicates that there were no significant changes in the company's operational situation during the reporting period [4]. Important Events - The company will hold a semi-annual performance briefing on August 28, 2025, to discuss its financial results and operational performance with investors [8][10]. - Investors can submit questions for the briefing from August 21 to August 27, 2025, through the Shanghai Stock Exchange Roadshow Center [9][10].

证券代码：603351 证券简称：威尔药业 公告编号：2025-023 南京威尔药业集团股份有限公司 关于2025年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、 主要产品和原材料的价格变动情况 （一）主要产品销售价格变动情况 单位：元/吨（不含税） | 主要产品 | 2025 年 | 1-6 | 月 | 2024 年 | 1-6 | 月 | 变动比例 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 平均售价 | | | 平均售价 | | | | | 主要产品 | 年 月 2025 1-6 平均售价 | 2024 | 年 月 1-6 平均售价 | 变动比例 | | --- | --- | --- | --- | --- | | 1、合成润滑基础油 | 14,953.22 | | 15,992.14 | -6.50% | | 其中：机械类 | 16,415.59 | | 18,069.94 | -9.16% | | 非机械类 | ...

南京威尔药业集团股份有限公司 关于召开 2025 半年度业绩说明会的公告 证券代码：603351 证券简称：威尔药业 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 08 月 21 日至 08 月 27 日 16:00 前登录上证路演中心 网站首页点击"提问预征集"栏目或通过公司邮箱 wellyy@wellnj.com 进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 一、说明会类型 南京威尔药业集团股份有限公司（以下简称"公司"）已于 2025 年 8 月 20 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司经营 成果、财务状况，公司拟召开 2025 半年度网上业绩说明会，针对 2025 半年度的 经营成果及财务指标的具体情况与投资者进行互动交流与沟通，在信息披露允许 的范围内就投资者关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 08 月 28 日 09:00-10:00 （二）会 ...

南京威尔药业集团股份有限公司 2025 年半年度报告 公司代码：603351 公司简称：威尔药业 南京威尔药业集团股份有限公司 2025 年半年度报告 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人吴仁荣、主管会计工作负责人唐群松及会计机构负责人（会计主管人员）杨轶 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 二〇二五年八月 中国 南京 1 / 152 南京威尔药业集团股份有限公司 2025 年半年度报告 重要提示 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，敬请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性 ...